Quad healing blend
Quad healing blend (TB-500 + BPC-157 + KPV + GHK-Cu, low copper ratio)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Quad blend, Low-copper KLOW
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Same four peptides as KLOW, mixed a totally different way. A typical vial is 5 mg TB-500, 5 mg BPC-157, 10 mg KPV and 5 mg GHK-Cu. That is 25 mg total. The copper peptide is a fifth of the powder here. In KLOW it is closer to two thirds. Same ingredient list, different product.
What people take it for
- Healing an injury.
- Calming the gut.
- Skin and hair, from the copper.
- People who want KLOW with less copper.
What the trials actually showed
No study has tested any four peptide mix, in people or animals. The parts each have a thin file. The best test of the copper peptide gave it as a cream to 13 people after laser skin work. Blinded raters saw no real change in redness, wrinkles or skin quality. Only the patients' own scores liked it. The one trial running now is a gel on small wounds in 60 healthy adults. KPV has no human data at all. BPC-157 has five human studies with fewer than 110 people, none using a shot under the skin. TB-500 has none. Now the math, because it is the point. Copper metal is about 16 percent of the copper peptide by weight. So 5 mg of copper peptide is about 0.8 mg of copper in the whole vial. A standard KLOW vial holds close to 7.9 mg. Mix the 25 mg with 2.5 mL of water and every unit mark carries 20 micrograms each of TB-500, BPC-157 and copper peptide, plus 40 micrograms of KPV.
What people report
Reports, not trial results
The good
- Less stinging at the shot site than the copper heavy blends.
- Gut symptoms settling, which people credit to the doubled KPV.
- Joint and tendon relief in the first weeks.
- Less skin and hair change than on copper heavy vials, which fits having a fifth of the copper.
The bad
- No effect at all.
- You still cannot turn one part down. One plunger moves all four.
- You still cannot tell which of four things did anything.
- Injected copper has never been studied over months. If you have Wilson's disease, any other copper problem, or a high copper on your labs, stay away.
Where these come from: Clinic write-ups, seller listings and peptide forums. People talking, not trial data, and usually while running other things too.
My bottom line
The lesson here is bigger than the vial. Two products with the same four ingredients can be ten times apart on the one that matters. Read the milligrams, not the name.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The same four peptides as KLOW at a completely different ratio, typically 5 mg TB-500, 5 mg BPC-157, 10 mg KPV and 5 mg GHK-Cu in a 25 mg vial. Copper peptide is 20% of the powder here against 62.5% in KLOW, which is roughly 0.8 mg of elemental copper per vial instead of 7.9 mg. No study has tested any four-peptide combination in any species.
This vial matters because of what it proves about the category. KLOW and this product contain the same four ingredients. The label on one says 50 mg of copper peptide and 10 mg each of the rest; the label on the other says 10 mg of KPV and 5 mg each of the rest. They are not the same product in any sense that matters to a body, and no name on either vial tells you which you are holding.
Run the arithmetic. Twenty five milligrams of powder: 5 mg TB-500, 5 mg BPC-157, 10 mg KPV, 5 mg GHK-Cu. GHK-Cu is 20% of the mass, against 62.5% in the standard KLOW vial. Copper is close to 16% of the GHK-Cu complex by mass, so a 5 mg load is roughly 0.8 mg of elemental copper in the whole vial. The US dietary reference intake for copper is 0.9 mg a day and the tolerable upper intake level is 10 mg a day, both figures for copper swallowed, where the gut regulates absorption. An injection skips that regulation, so those numbers are scale rather than a limit, but the scale is the point: this vial holds about a tenth the copper of the product it is modelled on.
Reconstitute the 25 mg with 2.5 mL and you have 10 mg/mL of total powder. One unit on a 100 unit insulin syringe carries 20 micrograms each of TB-500, BPC-157 and GHK-Cu, and 40 micrograms of KPV. A 12.5 unit draw gives 250 micrograms each of the three and 500 micrograms of KPV.
What has not changed is the structural problem. The ratio is still fixed, you still cannot lower the copper without lowering the peptide you bought the vial for, and you still cannot attribute anything that happens to any one of four ingredients. And the evidence base is still the same four thin single-agent literatures: a cream study that failed its blinded endpoints, mouse colitis, a rodent repair model, and a seven amino acid fragment of a different protein.
Mechanism of action
Four assumed-additive mechanisms in one solution. GHK-Cu carries copper into tissue and drives collagen and glycosaminoglycan production in culture and in rodent wound chambers. KPV suppresses NF-kB and MAP kinase signalling. BPC-157 and the actin-binding fragment act through the pathways on their own pages. Nothing published describes the four together, and an acidic copper complex sharing a vial with three other peptides is a formulation question nobody has answered in public.
Human evidence
None for any four-peptide combination. The component record is the same one KLOW carries, and it is thinner than either product page suggests.
- The blend: no study, no registration, in any species.
- GHK-Cu: all human data is topical. A randomised trial in 13 patients after CO2 laser resurfacing found no significant difference in redness, wrinkles or overall skin quality on blinded assessment, with only the patients' own questionnaire favouring it at P = 0.04. The one registered trial is a gel on punch-biopsy wounds and has not reported.
- KPV: no human data of any kind, no registered study.
- BPC-157: five human studies counted by FDA, fewer than 110 subjects, none subcutaneous, none longer than two weeks.
- TB-500: no human study; the product is a seven amino acid fragment of thymosin beta 4.
What this does not tell you: The copper question is unanswered at every ratio. No study has measured serum copper or ceruloplasmin in a person injecting GHK-Cu, at 5 mg a vial or at 50.
What it has been measured to do
Measured in animals or cells, not yet in people
Real results that answer a different question from a trial. Where a human trial is missing on a compound nobody can patent, the reason is usually that no sponsor would ever recover the cost of running one. The record on this one is set out below.
- Losing weight1 preclinical study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with Quad healing blend, what they expect, and what goes wrong. The full account, including the negative reports, is below.
34 of the 36 indexed goals have no study of any kind behind Quad healing blend
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about Quad healing blend and one of these did not come from a study cited here.
Reading the research record
The useful lesson from this product is a general one about the category: the ingredient list is not the product. Two vials sharing four ingredients can differ fivefold or tenfold in what a draw delivers of any one of them, and nothing in the naming convention signals that. A person who read about KLOW and bought this, or the reverse, has bought a materially different thing and will have no way to know.
On copper specifically, the lower load is a real reduction in an unquantified risk rather than the removal of one. Anyone with Wilson's disease, another copper handling disorder, a raised serum copper or a low ceruloplasmin should avoid injected copper peptides at any ratio, and almost nobody buying a blend has had those measured.
The evidence, charted
Fig. 1a · evidence scale
13people, across 1 human study cited here
- 2006 · Archives of Facial Plastic Surgery13100%
The whole total is one study of 13. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
1 of 5 citations here is human work, the rest are not.
- Human · given to people120%
- Animal · given to animals120%
- Review · summarises other work360%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2006 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- A mixture. GHK-Cu is about 403 Da as the copper complex, KPV about 342 Da, BPC-157 about 1,419 Da, and the fragment sold as TB-500 about 889 Da.
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. Four components with different clearance and no pharmacokinetic study of the mixture.
No amino acid sequence is on file for Quad healing blend, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
40%of a 25 mg Quad healing blend vial is KPV
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Human2006
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Thirteen patients randomised after circumoral CO2 laser resurfacing to a regimen with or without GHK-Cu skin care. Computer analysis and blinded evaluators found no significant difference in resolution of redness, and objective evaluation found no significant improvement in wrinkles or overall skin quality. Only the patients' own questionnaire favoured GHK-Cu, at P = 0.04.
Archives of Facial Plastic Surgery - Review2018
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart and Margolina review the gene and cell data behind GHK-Cu: collagen and elastin synthesis, fibroblast support, anti-inflammatory signalling. All of it topical or in vitro, none of it injected, and none of it establishing a dose for an injection.
International Journal of Molecular Sciences - Review2024
Is Copper Still Safe for Us? What Do We Know and What Are the Latest Literature Statements?
Total body copper is 50 to 120 mg, the safe upper limit of average intake is put at 10 to 12 mg a day against a reference limit of 0.9 mg a day, and the biological half-life from diet runs 13 to 33 days. The review notes that even small changes in copper concentration can carry significant toxicity. It covers dietary and environmental copper, not an injected peptide complex.
Current Issues in Molecular Biology - Animal2008
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
In two mouse colitis models KPV produced earlier recovery, greater body-weight regain, fewer inflammatory infiltrates and lower myeloperoxidase activity in colon tissue. Mice, KPV given alone, nothing here about a blend or about people.
Inflammatory Bowel Diseases - Review2026
FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.
FDA
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Less injection site stinging than the copper-heavy blends, credited to the smaller copper load.
- Gut symptoms improving, credited to the doubled KPV.
- Joint and tendon relief in the first weeks.
- Less of the skin and hair change people report on copper-dominant vials, which is consistent with a fifth of the copper peptide.
- No effect at all.
Sources: Clinic write-ups, vendor listings and peptide forums. Uncontrolled self-reports, frequently alongside other compounds. Reports, not evidence.
Frequently asked questions
Is this the same as KLOW?
Same four ingredients, different product. KLOW is usually 50 mg of copper peptide with 10 mg each of the other three. This is usually 10 mg of KPV with 5 mg each of the rest. Copper peptide is 62.5% of KLOW by mass and 20% here.
How much copper is in it?
Copper is about 16% of the GHK-Cu complex by mass, so a 5 mg load is roughly 0.8 mg of elemental copper in the vial. Dietary reference points are 0.9 mg a day with an upper limit of 10 mg a day, but those describe copper swallowed, where the gut regulates absorption. No study has measured blood copper in anyone injecting this.
What does one unit deliver?
On a 25 mg vial reconstituted with 2.5 mL, each unit mark carries 20 micrograms each of TB-500, BPC-157 and GHK-Cu, and 40 micrograms of KPV.
Has the four-way combination ever been tested?
No, at any ratio, in any species. Every claim on any four-peptide blend page is assembled from four separate single-agent literatures.
Who should not use a copper blend at all?
Anyone with Wilson's disease or another copper handling disorder, anyone with a raised serum copper or a low ceruloplasmin, and anyone who has not had those measured and does not intend to.